Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological disorders marked by progressive cytopenias and risk of transformation to acute myeloid leukaemia (AML). Best supportive care (BSC) remains the mainstay of therapy. The pyrimidine analogue azacitidine was the first drug to demonstrate that a change in the natural history of MDS is possible and was the first chemotherapeutic agent approved by the US Food and Drug Administration for the treatment of MDS. Azacitidine, a hypomethylating agent, has shown to reduce proliferation and induce apoptosis of dysplastic cells. The Cancer and Leukemia Group B (CALGB) 9221 and AZA-001 trials demonstrated superiority of azacitidine over BSC and conventional care regimen, respectively. Various studies have demonstrated that azacitidine has better tolerability with comparable efficacy in terms of conventional therapy in older AML patients. Azacitidine is well tolerated even in the elderly patients. Cytopenias were the most commonly occurring haematological adverse events. Gastrointestinal adverse events (AEs) (e.g. nausea, vomiting and diarrhoea) and injection-site reactions were the most commonly occurring nonhaematological AEs. The review summarises the current role of azacitidine in the management of MDS and AML.
The myelodysplastic syndromes (MDS) are a heterogeneous group of haematological disorders characterised by ineffective haematopoiesis with associated cytopenias and a hypercellular bone marrow (BM) with dysplastic changes. 1 Patients with MDS have a variable reduction in the production of normal red blood cells (RBCs), platelets, and mature granulocytes. This often results in a variety of systemic consequences including anaemia, bleeding and an increased risk of infection. 2, 3 The incidence of MDS in the US has been estimated as 4.1/100,000 population. The incidence rises with increasing age: 4.9 for people aged 50 to 70 years and 22.8 for people older than 70 years. 4 There are two systems to classify MDS: the older French-American-British (FAB) classification 5 and the more recent World Health Organization (WHO) classification. 6 The FAB system classified MDS into five main subtypes:
• Refractory anaemia (RA) (<5 % marrow blasts);
• RA with ring sideroblasts (RARS) (<5 % marrow blasts);
• RA with excess blasts (RAEB) (5-20 % marrow blasts);
• RAEB in transformation (RAEB-T) (21-30 % marrow blasts); and
• Chronic myelomonocytic leukaemia (CMML) (5-20 % marrow blasts).
The 2008 WHO system further subdivided MDS, based on factors such as the presence or absence of multilineage dysplasia and the percentage of BM blasts, into the following subtypes:
• Refractory cytopenia with unilineage dysplasia (including refractory anaemia, refractory neutropenia and refractory thrombocytopenia) (<5 % marrow blasts);
• RARS (<5 % marrow blasts);
• Refractory cytopenia with multilineage dysplasia (<5 % marrow blasts);
• RAEB-1 (5-9 % marrow blasts);
• RAEB-2 (10-19 % marrow blasts);
• MDS, unclassified (<5 % marrow blasts); and
• MDS associated with isolated del(5q) (<5 % marrow blasts).
In addition, ≥30 % marrow blasts are required for a diagnosis of acute myeloid leukaemia (AML) using the FAB system, whereas only ≥20 % marrow blasts are required for an AML diagnosis using the WHO system. Table 1 gives an overview of comparison of the FAB and WHO classifications for MDS.
Existing Treatment Options of Myelodysplastic Syndromes
The main treatment option for MDS has been best supportive care
(BSC), which aims to alleviate the negative effects of cytopenia and to increase quality of life (QOL). BSC remains the backbone of MDS therapy for all patients despite the emergence of novel drugs. This includes RBC transfusions to alleviate symptoms of anaemia, adequate iron chelation therapy to reduce haemosiderosis, platelet transfusions to decrease risk of haemorrhage in thrombocytopenic patients and control of infections by the use of antibiotics and granulocyte-colony stimulating factor (G-CSF). 10 The only proved curative approach for MDS is allogeneic stem cell transplant (ASCT), 11 but its use has been limited by donor availability, advanced age of most patients with this disorder and higher costs.
SCT-related mortality is in the range of 30 % to 40 % in most studies.
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Given these limitations ASCT is not an adequate option for most patients with higher-risk MDS. Other less-intensive treatment options include non-intensive chemotherapy (non-IC), immunomodulatory agents or immunosuppressive therapy. These approaches do not offer significant survival benefit in higher-risk MDS patients.
Demethylating agents such as azacitidine and 5-aza-deoxycitidine 
Pharmacodynamic Properties
Azacitidine is a pyrimidine nucleoside analogue of cytidine that is phosphorylated intracellularly to its active form, azacitidine triphosphate. The azacitidine molecule exerts its antineoplastic activity by hypomethylation of the DNA and a cytotoxic effect on abnormal haematopoietic cells in the BM. 13 Following cellular uptake, azacitidine gets converted into azacitidine triphosphate, which is incorporated into the RNA. About 10-20 % is converted to 5-aza-2-deoxycytidine triphosphate via the enzyme ribonucleotide reductase and gets incorporated into the DNA. This results in the formation of adducts between the DNA and DNA methyl transferase 1 (DNMT-1). At high doses, the DNA is not able to recover and cell death occurs. However, at lower doses the formed adducts are degraded by the proteosome, after which the DNA is restored. DNA synthesis is then resumed in the absence of DNMT-1. As a consequence the aberrant DNA methylation pattern can no longer be reproduced toward the daughter strands.
14 In this way, a low dose of azacitidine is able to induce re-expression of previously silenced genes. Reactivation of cell cycle-regulating genes that were initially silenced due to hypermethylation may induce cell differentiation, reduce proliferation and/or increase apoptosis of the daughter cells.
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Pharmacokinetic Properties Absorption
Absorption of azacitidine is rapid after subcutaneous (SC) administration.
A maximum plasma concentration of 750 ± 403 ng/ml is attained 
Distribution
For azacitidine the mean volume of distribution after IV administration was about 76 l. 16 A retrospective study examined the feasibility of therapy with azacitidine or decitabine in patients with renal insufficiency (creatinine clearance ≤59 ml/minute). 17 Toxicity rates were comparable to previous reports in patients with adequate renal function. Standard doses of hypomethylating agents were tolerated by most patients. However, dose reductions and treatment interruptions were required for patients with severe renal insufficiency (i.e., creatinine clearance ≤30 ml/minute). This group experienced more treatment-related toxicities, mainly myelosuppression and worsening of the renal function. 17 There have been no studies on the effects of age and gender on azacitidine pharmacokinetics. The pharmacokinetics of azacitidine in Japanese patients with MDS were similar to those in Caucasian patients with MDS. In the CALGB 9221 trial, patients with MDS who received azacitidine had a significantly higher overall response rate than those receiving supportive care alone (60 % versus 5 %) (see Table 3 ).
The CR rate and the CR plus PR rate were also significantly higher with azacitidine than with supportive care alone.
The median time to treatment failure (21 versus 12 months) and to AML transformation or death (9.1 versus 3.8 months) were significantly longer in patients receiving azacitidine than in those receiving supportive care (see Table 3 ).
There was no significant difference in the median duration of overall survival (OS) between patients receiving azacitidine and those receiving supportive care (20 versus 14 months) (see Table 3 ), although these results were confounded by the 49 supportive care recipients who crossed over to azacitidine during the course of the trial. In a landmark analysis designed to eliminate this confounding effect, the median duration of OS was significantly longer in patients initially randomised to azacitidine than in patients initially randomised to supportive care who never crossed over to azacitidine or only crossed over after 6 months had elapsed (18 versus 11 months; p=0.03) (see Table 3 ).
Patients who achieved a complete or PR by definition did not require any Azacitidine was effective in the treatment of patients with higher-risk MDS/AML. Median OS was significantly better with azacitidine than with conventional care (see Table 4 of patients preselected to receive LDAC (n=94) revealed a 2-year OS rate of 54 % with azacitidine and 27 % with LDAC.
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The median time to AML transformation was significantly longer in patients receiving azacitidine than in those receiving conventional care (17.8 versus 11.5) (see Table 4 ). When analysed according to the preselected conventional care strategy, the median time to AML transformation was significantly longer with azacitidine than with BSC Table 4 ).
Rates of any remission (29 % versus 12 %), CR (17 % versus 14 %) or PR (12 % to 8 %) and rates of any (49 % versus 29 %), major erythroid (40 % versus 11 %) or major platelet (33 % versus 14 %) improvement were significantly higher in patients receiving azacitidine than in those receiving conventional care (see Table 4 ).
Therapeutic Efficacy in Acute Myeloid Leukaemia -Landmark Studies
AML is associated with poor prognosis in elderly patients with 2-year OS rates of approximately 10 %. There is lack of adequate treatments for AML patients. IC is generally limited to only 30 % to 60 % of older AML patients due to poor performance status, significant comorbidities, adverse tumour cytogenetics and poor treatment tolerability, leading to treatment-related mortality rates of 10 % to 25 %. Therefore, new treatment options are needed for these patients. Azacitidine-treated patients spent fewer days in the hospital (median Thus, from the available data it can be concluded that azacitidine treatment is associated with a comparable OS but higher tolerability, 
Hypomethylating Agents -Azacitidine versus Decitabine
In an adjusted indirect meta-analysis by Kumar The decitabine group did not show such superiority. Azacitidine was a favourable factor in patients with higher risk (IPSS value of 3) or older than 75 years, treatment with azacitidine was a favourable factor. 
Adverse Events Associated with Azacitidine
Haematological toxicity was the most commonly occurring adverse event (AE) in azacitidine recipients.
In the CALGB 9221 trial, grade 3-4 leukopenia, granulocytopenia and thrombocytopenia occurred in 43 %, 58 % and 52 % of azacitidine recipients, respectively. They were managed by interruption of azacitidine dosing in 23 % patients and azacitidine dose reduction in 11 % of patients.
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Among azacitidine recipients, nadir haemoglobin levels, platelet counts and absolute neutrophil counts occurred in a median of 14-15 days in the AZA-001 trial and a median of 15-16 days in the CALGB 9221 trial.
In the AZA-001 trial, anaemia and thrombocytopenia were managed by blood transfusions in 87 % and 29 %, respectively. Infections were treated with antibiotics (levofloxacin, ciprofloxacin). Neutropenia was treated with G-CSF in 13 % of patients.
The most common non-haematological AEs were gastrointestinal (GI) and injection-site reactions. Anti-emetics (ondansetron, metoclopramide, domperidone), stool softeners (lactulose) and anti-diarrhoeal (loperamide) were used to manage GI adverse effects in the CALGB and AZA-001 trials. 32 Haematological and non-haematological AEs with azacitidine decreased in frequency as treatment continued. 32 In the AZA-001 trial, the rate of infections requiring IV antimicrobials was significantly lower in patients receiving azacitidine than in those receiving conventional care (0.60 versus 0.92 per patient-year; p=0.0032) in adults with higher-risk (i.e. IPSS intermediate-2-risk or highrisk classification) MDS/AML. 21 The rate of hospitalisations was also significantly (p<0.0001) lower in azacitidine recipients than in patients receiving conventional care (29 % versus 39 % per patient-year).
The majority of AEs reported in the AZA-001 and CALGB 9221 studies were transient and were managed by either supportive care measures, dose delays or, less commonly, dose reductions. Early detection and prompt management of AEs would allow patients to continue therapy and offer maximum benefit of azacitidine therapy. Azacitidine is a considerable treatment option for AML and offers comparable OS but better tolerability in older patients compared with IC.
Summary and Place of
In older adult patients with low BM blast count (20 % to 30 %) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with conventional care.
Azacitidine was generally well tolerated in patients with MDS, including in the elderly. Cytopenias were the most commonly occurring AE in azacitidine recipients, with GI AEs (e.g. nausea, vomiting and diarrhoea) and injection-site reactions among the most commonly occurring nonhaematological AEs. However, most of these are transient and can be managed by supportive care measures or delay in dosing.
In conclusion, azacitidine is an important agent for use in the treatment of patients with MDS/AML. ■
